CBS Therapeutics Inc.

CBS Therapeutics is start-up company, developing first-in-class inhibitors of Cystathionine-?-synthase, that could synergize with existing therapies to treat both KRAS-mutant and wild-type metastatic colorectal cancer.

CBS Therapeutics is promoted by University of Texas Medical Branch at Galveston (UTMB) researchers - Csaba Szabo and Mark R. Hellmich who recently identified that H2B S is also a key agent in colon cancer metabolism.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Website
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
6 Cadena Court, TX 77554-6302
Galveston
United States
Email
Contact Number
+1 206 291 2959

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Jan 2014, CBS Therapeutics received phase I STTR grant from NIH for the screening for Novel cystathionine-?-synthase (CBS) Inhibitors for cancer therapy.